Try
Stoke Therapeutics, Inc.
STOKUnited States
30 filed reports · 227 financial concepts · 1 earnings calls · 0 media appearances
Filed reports
30 reports · Jun 2019 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 22 | 2,300 | Jun 2019 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 7 | 1,813 | Dec 2019 to Dec 2025 |
| Current · 8-KSEC EDGAR | 1 | 2 | Jun 2026 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 3, 2026 | 270 | Open |
| FY2026 Q2 | 8-K | Jun 30, 2026 | Aug 3, 2026 | 2 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 7, 2026 | 159 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Mar 16, 2026 | 447 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 4, 2025 | 183 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 12, 2025 | 107 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 13, 2025 | 107 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Mar 18, 2025 | 249 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 5, 2024 | 107 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 7, 2024 | 82 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 6, 2024 | 85 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Mar 25, 2024 | 242 | Open |
Financial data
227 concepts · 4,115 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial224 concepts · 3,995 facts · Dec 2017 to Jul 2026
- Stockholders equity (US GAAP)44 · Dec 2017 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents including disposal group and discontinued operations43 · Dec 2017 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value42 · Mar 2018 to Jun 2026
- Net income loss42 · Mar 2018 to Jun 2026
- Operating expenses (US GAAP)42 · Mar 2018 to Jun 2026
- Operating income loss42 · Mar 2018 to Jun 2026
- Allocated share based compensation expense41 · Jun 2018 to Jun 2026
- Cash and cash equivalents at carrying value41 · Jun 2018 to Jun 2026
- Research and development expense41 · Jun 2018 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect40 · Sep 2018 to Jun 2026
- Depreciation40 · Sep 2018 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets40 · Sep 2018 to Jun 2026
- Net cash provided by used in financing activities40 · Sep 2018 to Jun 2026
- Net cash provided by used in investing activities40 · Sep 2018 to Jun 2026
- Net cash provided by used in operating activities40 · Sep 2018 to Jun 2026
- Payments to acquire property plant and equipment40 · Sep 2018 to Jun 2026
- Proceeds from stock options exercised40 · Sep 2018 to Jun 2026
- Profit loss40 · Sep 2018 to Jun 2026
- Share based compensation40 · Sep 2018 to Jun 2026
- Stock issued during period value stock options exercised40 · Mar 2018 to Jun 2026
- Common stock par or stated value per share39 · Dec 2018 to Jun 2026
- Common stock shares authorized39 · Dec 2018 to Jun 2026
- Accounts payable current38 · Dec 2018 to Jun 2026
- Accrued and other current liabilities38 · Dec 2018 to Jun 2026
Product1 concepts · 117 facts · Dec 2023 to Jun 2026
- Operating expenses (US GAAP)117 · Dec 2023 to Jun 2026
KPI2 concepts · 3 facts · Jun 2026
- Clinical Trial Participants2 · Jun 2026
- Clinical Trial Sites1 · Jun 2026
Segments
117 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or service11 members · 117 facts
- ADOA13 · Dec 2023 to Jun 2026
- MECP213 · Dec 2023 to Jun 2026
- Other External Program Costs13 · Dec 2023 to Jun 2026
- Other Non Program Costs Research And Development13 · Dec 2023 to Jun 2026
- Payroll And Other Personnel Costs Research And Development13 · Dec 2023 to Jun 2026
- SYNGAP113 · Dec 2023 to Jun 2026
- Zorevunersen13 · Dec 2023 to Jun 2026
- Other Non Program Costs General And Administrative7 · Dec 2023 to Dec 2025
- Payroll And Other Personnel Costs General And Administrative7 · Dec 2023 to Dec 2025
- Other Non Program Costs Sales General And Administrative6 · Sep 2024 to Jun 2026
- Payroll And Other Personnel Costs Sales General And Administrative6 · Sep 2024 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
1 calls · Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 3, 2026
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.